Journal Article

Efficacy of Intravenous Infusion of Doripenem

Marcos I. Restrepo

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 49, issue Supplement_1, pages S17-S27
Published in print August 2009 | ISSN: 1058-4838
Published online August 2009 | e-ISSN: 1537-6591 | DOI:
Efficacy of Intravenous Infusion of Doripenem

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology


Show Summary Details


Initial treatment of nosocomial pneumonia (NP), including ventilator‐associated pneumonia (VAP), is usually empirical. The use of a broad‐spectrum antibiotic regimen to treat NP‐VAP that is active against suspected multidrug‐resistant pathogens maximizes the likelihood of a favorable outcome. In a post hoc analysis of pooled data from 2 prospective, randomized, open‐label, phase 3 NP‐VAP trials, doripenem, a new broad‐spectrum carbapenem with antipseudomonal activity, demonstrated noninferiority to standard comparator regimens (imipenem and piperacillin‐tazobactam) with regard to clinical and microbiological outcomes. In subgroup analyses, doripenem continued to show noninferiority to the comparator drugs in achieving clinical and microbiological cures in populations at high risk of multidrug‐resistant infection, such as patients with late‐onset VAP (defined as patients who develop VAP >5 days after intubation) or those with NP‐VAP caused by Pseudomonas aeruginosa or complicated by bacteremia. Overall, the clinical data indicate that doripenem has the potential to be an important option in the treatment of NP, including VAP.

Journal Article.  5787 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.